Sky View Investment Advisors, LLC Enlivex Therapeutics Ltd. Call Options Transaction History
Sky View Investment Advisors, LLC
- $698 Million
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ENLV
# of Institutions
26Shares Held
2.81MCall Options Held
79.1KPut Options Held
0-
Armistice Capital, LLC New York, NY1.41MShares$1.47 Million0.03% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny612KShares$636,6880.0% of portfolio
-
Citizens Financial Group Inc231KShares$240,6800.0% of portfolio
-
Morgan Stanley New York, NY219KShares$227,9140.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny168KShares$175,1270.0% of portfolio
About Enlivex Therapeutics Ltd.
- Ticker ENLV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,403,200
- Market Cap $19.1M
- Description
- Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2...